Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging
Status:
Terminated
Trial end date:
2018-07-20
Target enrollment:
Participant gender:
Summary
The principal aim of this study is to investigate the cardiac uptake of 89Zr-GSK2398852 in
subjects with transthyretin cardiomyopathy amyloidosis (ATTR-CM), and its biodistribution to
other organs. Low doses of GSK2398852 will be co-administered at levels not high enough for
therapeutic benefit. This study will be conducted in two parts: Part A and Part B. Subjects
in Part A will participate in up to two dosing sessions and subjects in Part B will
participate in one dosing session. Subjects will undergo up to 3 PET scans at varying
intervals after 89Zr-GSK2398852 administration. The total duration of study will be
approximately 3 to 4 months for subjects in Part A and approximately 2 months for subjects in
Part B. Part B of the study will be triggered based on data obtained in Part A and other
emerging data.